eligibility_summary
Adults (≥18) with physician-confirmed severe uncontrolled eosinophilic asthma on high-dose ICS+LABA, prescribed but not yet started benralizumab, able to consent and complete paper PROs. Exclude significant non-asthma lung disease (e.g., COPD, bronchiectasis, IPF, pulmonary HTN, A1AT deficiency, malignancy, nasal polyps/allergic rhinitis/atopic dermatitis allowed), other interventional trials (except registry), limiting conditions, other asthma biologics (≥30-day washout), and pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: benralizumab (Fasenra) — an afucosylated humanized IgG1κ monoclonal antibody (biologic). Mechanism of action: binds IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils, blocking IL‑5 signaling and inducing potent antibody‑dependent cell‑mediated cytotoxicity (ADCC) via NK cells, leading to near‑complete depletion of circulating and airway eosinophils and reduction of type‑2 eosinophilic inflammation. Cells/pathways targeted: primary targets are eosinophils (and to a lesser extent basophils), pathway is the IL‑5/IL‑5R axis within the Th2/Type‑2 inflammatory cascade relevant to severe eosinophilic asthma. Trial context: prospective, real‑world observational study capturing patient‑reported outcomes in adults with severe uncontrolled eosinophilic asthma starting benralizumab, treatment per local label, no study drug supplied.